Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-02 02:07:032021-02-04 02:08:11Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
D-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-02-02 01:57:462021-02-04 01:58:30CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
Link to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-27 01:55:352021-02-04 01:56:37Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs
Link to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-20 02:20:362021-02-04 02:21:31Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting
Link to Full Article Cambridge, United Kingdom – 14 January 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-14 02:01:552021-02-04 02:03:17Leading advocacy professionals to ensure patient remains central to Congenica’s approach
Link to Full Article Cambridge, United Kingdom – 12 January 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announced it has launched a local cloud solution that will enable researchers in China to perform more efficient genomic analysis at scale, helping to improve […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-12 02:57:012021-01-19 02:57:58Congenica Local Cloud Solution to Enable High-quality, Scalable Genomic Analysis in China
Link to Full Article Melbourne, Australia; 12 January 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic product based on Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. In August 2018, Acrux submitted an Abbreviated New Drug Application (‘ANDA’) to seek approval from […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-01-12 02:41:222021-01-19 02:46:51Acrux receives FDA approval for its generic testosterone topical solution
Link to Full Article Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders. The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement. ACR is now hoping to raise an additional $2 […]
Link to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]
Link to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]
Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]
CalciMedica Presents New Clinical Data Demonstrating Improved D-Dimer Biomarker Levels with Auxora™ in Severe COVID-19 Pneumonia at the 50th Critical Care Congress
/in CalcimedicaD-dimer levels have been correlated with disease severity and risk of mortality in patients with COVID-19 Treatment with Auxora improved D-dimer levels in patients with severe COVID-19 pneumonia LA JOLLA, Calif., February 2, 2021 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of severe […]
Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company’s Bacteriophage Development Programs
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Jan. 27, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has entered into a securities purchase agreement to sell Armata common stock and warrant securities to Innoviva […]
Saluda Medical Announces Highlights from 2021 North American Neuromodulation Society (NANS) Meeting
/in Saluda MedicalLink to Full Article Artarmon, Australia – January 20, 2021 – Saluda Medical Pty Limited (“Saluda Medical”), the market leader in the development of closed-loop spinal cord stimulation for the treatment of chronic pain, announced scientific highlights from the 2021 North American Neuromodulation Society (NANS 2021) Virtual Meeting, including real-world European commercial results and sub-analyses of 24-month […]
Leading advocacy professionals to ensure patient remains central to Congenica’s approach
/in CongenicaLink to Full Article Cambridge, United Kingdom – 14 January 2021 – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces the launch of a Patient Advocacy and Engagement Advisory Board. Working with the Congenica Board of Directors and wider senior leadership team, this group […]
Congenica Local Cloud Solution to Enable High-quality, Scalable Genomic Analysis in China
/in CongenicaLink to Full Article Cambridge, United Kingdom – 12 January 2021 Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announced it has launched a local cloud solution that will enable researchers in China to perform more efficient genomic analysis at scale, helping to improve […]
Acrux receives FDA approval for its generic testosterone topical solution
/in AcruxLink to Full Article Melbourne, Australia; 12 January 2021: Acrux Limited (ASX:ACR) (‘Acrux’ or the ‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has approved its generic product based on Perrigo’s Testosterone Topical Solution, 30mg/1.5mL. In August 2018, Acrux submitted an Abbreviated New Drug Application (‘ANDA’) to seek approval from […]
Acrux (ASX:ACR) pushes ahead with $2M SPP
/in AcruxLink to Full Article Acrux (ACR) is pushing ahead with its planned share purchase plan (SPP) by sending off a booklet to eligible shareholders. The pharmaceutical company first flagged plans to carry out a fundraise back in late-December, when it successfully netted $7.8 million via a placement. ACR is now hoping to raise an additional $2 […]
GEN INCODE APPOINTS NEW CHAIRMAN
/in GenInCodeLink to Full Article GENinCode UK Limited the privately-owned artificial intelligence cardiovascular disease company focused on the prevention of cardiovascular disease, announces today the appointment of Bill Rhodes as non-executive Chairman of the Company, effective 1 January, 2021. Bill Rhodes is a Chairman with a proven, demonstrable international track record in the Life Sciences and […]
Destiny Pharma Phase 2b trial of XF-73 completes recruitment
/in Destiny PharmaLink to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]